Localized prostate cancer is typically treated with moderately hypofractionated external beam radiotherapy, allowing patients to complete treatment within 6 weeks with outcomes comparable to those associated with conventionally fractionated radiotherapy, which requires up to 9 weeks to complete. Ultrahypofractionated radiotherapy can cut total treatment course times even further, to 4 to 5 total treatments (1-2 weeks).

But concern about acute radiotoxicities has slowed wider adoption of prostate cancer radiotherapy ultrahypofractionation. The HYPO-RT-PC trial had suggested ultrahypofractionation delivered via 3-dimensional conformal radiotherapy (3dCRT) increased acute toxicities compared to conventionally fractionated radiotherapy.1

The results from the international, randomized, phase 3, open-label PACE-B noninferiority study (ClinicalTrials.gov Identifier: NCT01584258), which delivered ultrahypofractionated treatment using stereotactic body radiotherapy (SBRT), indicated that prostate cancer radiotherapy can be safety shortened without increasing acute gastrointestinal or genitourinary radiotoxicities.2

Related Articles

Between 2012 and 2018, PACE-B enrolled 874 adult men with low-risk or intermediate-risk prostate adenocarcinoma and WHO performance status scores of 0 to 2, and who were not undergoing androgen deprivation, at 37 cancer centers in the United Kingdom, Ireland, and Canada.2 Patients were randomly assigned 1:1 to receive conventionally fractionated or moderately hypofractionated radiotherapy (78 Gy in 39 fractions over 8 weeks or 62 Gy in 20 fractions over 4 weeks; 441 individuals), or ultrahypofractionated SBRT (36.25 Gy delivered in 5 fractions over 1 to 2 weeks; 433 individuals).2

Grade 2 or higher severe adverse gastrointestinal events were recorded in 53 (12%) of the patients in the conventionally fractionated or moderately hypofractionated radiotherapy study control group vs 43 (10%) of 415 patients in the SBRT ultrahypofractionation group.2 Grade 2 or worse genitourinary radiotoxicities occurred in 118 (27%) of the control group versus 96 (23%) of the SBRT ultrahypofractionation group.2 No treatment-related deaths were reported.

PACE-B is a “very important study,” commented radiation oncologist Thomas Zilli, MD, of Geneva University Hospital in Switzerland. It is the first randomized trial comparing a SBRT ultrahypofractionation schedule and standard-of-care moderate hypofractionation radiotherapy, he noted.

PACE-B’s low overall acute toxicity data “show no difference” with standard moderate hypofractionation, Dr Zilli said.